Significance of the ORKA-001 Phase 2a EVERLAST-A Trial Results

Oruka Therapeutics' (ORKA) ORKA-001, a candidate treatment for moderate-to-severe plaque psoriasis, has demonstrated promising efficacy in the Phase 2a EVERLAST-A trial. At week 16, 63.5% (40 out of 63) of patients in the ORKA-001 treatment group achieved PASI 100, indicating complete skin clearance, and 83% achieved PASI 90, indicating near-complete clearance. These results are considered highly significant and demonstrate rapid and substantial improvement compared to existing treatments. Furthermore, the trial reported no serious treatment-emergent adverse events (TEAEs), confirming a favorable safety profile.

Differentiation from the Blockbuster Treatment Skyrizi

The results are particularly noteworthy when compared to AbbVie's (ABBV) Skyrizi, a blockbuster psoriasis treatment with approximately $18 billion in annual sales, in a cross-trial comparison. Skyrizi's historical clinical data showed a PASI 100 response rate of about 51%. In contrast, ORKA-001, an interleukin-23p19 (IL-23p19) monoclonal antibody, achieved a higher PASI 100 response rate of 63.5%, demonstrating superior efficacy. The drug also showed comparable skin improvement rates to UCB's (UCB) Bimzelx, suggesting a potential disruption of the market. This strong efficacy profile positions ORKA-001 as a potential disruptor to the current standard of care upon its potential launch.

Impact of a Once- or Twice-Yearly Dosing Regimen

A key strength of Oruka lies in its half-life extension technology, which maximizes the duration of drug effect. While Skyrizi, the current market leader, requires annual administration four times a year, ORKA-001 is projected to allow for a much longer dosing interval, potentially once or twice a year, based on initial clinical studies. This reduction in dosing frequency would significantly improve treatment compliance and quality of life for patients with chronic psoriasis, as well as reduce the number of hospital visits. This convenience is also expected to be a strong commercial incentive for payers and healthcare providers, leading to lower overall treatment costs.

Success of Paragon Spin-Out Companies and Commercialization Timeline

Oruka Therapeutics is a spin-out company of Paragon Therapeutics, which has also created other successful immunology companies such as Apogee Therapeutics and Spyre Therapeutics. Oruka is employing a focused strategy of developing optimized versions of existing blockbuster drugs in the dermatology space, specifically targeting plaque psoriasis and hidradenitis suppurativa. The approximately 20% surge in Oruka's stock price following the release of these positive data suggests that the market recognizes the value of this differentiated development platform. Oruka plans to release long-term follow-up data from this trial in the second half of 2026 and to publish the results of a Phase 2b (EVERLAST-B) trial to optimize the dosing regimen in 2027.